BIOCOVER ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  7.9% 6.9% 17.0% 12.4% 21.2%  
Credit score (0-100)  32 35 9 18 4  
Credit rating  BB BBB BB BB B  
Credit limit (kDKK)  -0.0 -0.0 -0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -833 -2,692 -264 433 43.2  
EBITDA  -1,570 -3,666 -1,531 215 -79.6  
EBIT  -2,344 -4,269 -2,331 215 -79.6  
Pre-tax profit (PTP)  -2,423.0 -4,442.5 -2,352.7 190.2 -78.7  
Net earnings  -2,615.7 -4,442.5 -2,352.7 190.2 -78.7  
Pre-tax profit without non-rec. items  -2,423 -4,442 -2,353 190 -78.7  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  184 0.0 0.0 0.0 0.0  
Shareholders equity total  778 2,245 -107 82.8 4.1  
Interest-bearing liabilities  2,777 2,277 188 45.5 0.0  
Balance sheet total (assets)  3,875 5,748 1,507 245 76.8  

Net Debt  2,777 2,277 -38.3 -141 -12.4  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -833 -2,692 -264 433 43.2  
Gross profit growth  -88.0% -223.1% 90.2% 0.0% -90.0%  
Employees  2 2 3 1 1  
Employee growth %  100.0% 0.0% 50.0% -66.7% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,875 5,748 1,507 245 77  
Balance sheet change%  -29.9% 48.3% -73.8% -83.7% -68.7%  
Added value  -1,569.9 -3,666.4 -1,530.8 1,015.8 -79.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -1,548 -1,345 -1,583 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 1.0 -1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  281.3% 158.6% 882.5% 49.7% -184.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -49.2% -88.7% -63.3% 23.2% -48.6%  
ROI %  -51.6% -105.7% -99.0% 136.2% -118.1%  
ROE %  -125.4% -293.9% -125.4% 23.9% -181.2%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  20.1% 39.1% -6.7% 33.8% 5.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -176.9% -62.1% 2.5% -65.4% 15.6%  
Gearing %  357.1% 101.4% -175.1% 54.9% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  4.6% 6.9% 1.8% 21.6% 2.6%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.5 0.3 0.9 1.5 1.1  
Current Ratio  0.8 1.4 0.9 1.5 1.1  
Cash and cash equivalent  0.0 0.0 226.4 186.3 12.4  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -636.8 1,463.0 -107.4 82.8 4.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -785 -1,833 -510 1,016 -80  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -785 -1,833 -510 215 -80  
EBIT / employee  -1,172 -2,134 -777 215 -80  
Net earnings / employee  -1,308 -2,221 -784 190 -79